Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs). This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not ...

Researchers from the Children’s Medical Center Research Institute at the University of Texas Southwestern discovered a potential treatment for patients with non–small cell lung cancer (NSCLC) who have ...

“KRAS is a frequent genomic driver in lung adenocarcinoma,” said Michael Redman, Executive Vice President and Chief Operating Officer of Genprex. “LKB1 (also known as STK11) is a distinct subgroup of ...

A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer.

Researchers have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC). These findings could pave the way for new treatments for patients with ...

Norton Thoracic Institute researchers believe they have discovered a new approach to treating an aggressive and difficult-to-treat type of lung cancer. They published their study (“WEE1 Kinase ...

Researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC) ...

AUSTIN, Texas--(BUSINESS WIRE)-- Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer ...